Neurocrine Biosciences Inc (NBIX: NASDAQ)
$44.7 -1.25 | -2.72%
10/26/16 - 04:00 PM ET
890.17K / 766.00KVol / Avg. Vol:
45.95 / 45.95Open / Prev. Close:
44.65 - 46.56Today's Range:
31.25 - 58.4652 Wk Range:
Portfolios with NBIX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks With Big Insider Buy...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Drug Stock Winners of 2010
- UserKareem Portfolio
- UserSUPRATRADE Top 10 Micro Cap...
- UserBVF Inc.
- UserRAPTOR SPRTD-1110080822
Latest NBIX Headlines from TheStreet
- Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business! 04.07.16 | 07:04 pm
- Water-Logged And Getting Wetter Stock Of The Day: Neurocrine Biosciences (NBIX) 07.20.15 | 11:07 am
- Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock 05.14.15 | 09:05 am
- First Week of NBIX June 19th Options Trading 04.23.15 | 11:04 am
- Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference 03.30.15 | 08:03 pm
- Short Interest In Neurocrine Biosciences Drops 20.6% 03.11.15 | 03:03 pm
- Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options 12.24.14 | 12:12 pm
- 2 Big-Volume Biotech Stocks to Trade for Breakouts 09.25.14 | 09:09 am
- The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks 08.26.14 | 02:08 pm
- NBIX Crosses Above Key Moving Average Level 08.06.14 | 11:08 am
Press Releases for NBIX
- Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2015 Results - PR Newswire 07.22.15 | 01:07 pm
- Neurocrine Biosciences Provides Update On NBI-77860 Program For Congenital Adrenal Hyperplasia - PR Newswire 06.08.15 | 04:06 pm
- Neurocrine Biosciences, Inc. Announces Appointment Of Eric Benevich As Chief Commercial Officer - PR Newswire 06.02.15 | 08:06 am
- Neurocrine Biosciences To Present At The Jefferies 2015 Healthcare Conference - PR Newswire 05.27.15 | 03:05 pm
- Neurocrine Biosciences To Host Analyst And Investor Day In New York City On May 21, 2015 - PR Newswire 05.12.15 | 04:05 pm
- Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference - PR Newswire 05.08.15 | 01:05 pm
- Neurocrine Biosciences, Inc. Announces Appointment Of Dr. Bill Aurora As Vice President, Medical Affairs - PR Newswire 05.04.15 | 04:05 pm
- Neurocrine Biosciences To Present At The Deutsche Bank 40th Annual Health Care Conference - PR Newswire 04.30.15 | 01:04 pm
- Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2015 Results - PR Newswire 04.23.15 | 01:04 pm
- Neurocrine Biosciences And Mitsubishi Tanabe Pharma Announce Agreement To Develop And Commercialize VMAT2 Inhibitor NBI-98854 For Movement Disorders In Japan And Other Select Asian Markets - PR Newswire 03.31.15 | 10:03 pm
Partner Headlines for NBIX
- Healthcare ratings roundup - new coverage - SeekingAlpha 10.21.16 | 07:10 am
- AbbVie's Elagolix successful in two late-stage endometriosis studies; U.S. marketing application planned in 2017 - SeekingAlpha 10.19.16 | 10:10 am
- Neurocrine initiated with a Buy at Needham - The Fly 10.18.16 | 07:10 am
- Neurocrine recent weakness unwarranted, says BMO Capital - The Fly 10.13.16 | 09:10 am
- Neurocrine recent selloff a buying opportunity, says Leerink - The Fly 10.12.16 | 06:10 am
- Neurocrine's Ingrezza NDA for involuntary movement disorder accepted under Priority Review by FDA, action date April 11 - SeekingAlpha 10.11.16 | 07:10 am
- Alnylam downgraded to Equal Weight from Overweight at Barclays - The Fly 10.06.16 | 05:10 am
- Neurocrine reinstated with an Outperform at Leerink - The Fly 10.04.16 | 07:10 am
- Yellen And Clinton Combo To Take Market Higher - SeekingAlpha 09.29.16 | 12:09 am
- Positive data paves way for Teva SD-809 indication, says Leerink - The Fly 09.23.16 | 07:09 am